A History of Biopharmaceutics in the Food and Drug Administration 1968–1993
- 20 November 2009
- journal article
- review article
- Published by Springer Nature in The AAPS Journal
- Vol. 12 (1) , 44-50
Abstract
The history of biopharmaceutics is reviewed, beginning with its origin out of the Division of Clinical Research in The Bureau of Medicine. The reason for the creation of the Division of Biopharmaceutics, the certification of Food and Drug Administration authority over the functions it was to have, and the implementation of that authority are described. The determination of bioequivalence, the bioavailability decision rules, pharmacokinetics, and drug metabolism are explained. The reason for the development of the Scale-Up and Post Approval Regulations and how they were developed are also explained.Keywords
This publication has 25 references indexed in Scilit:
- Consideration of individual bioequivalenceJournal of Pharmacokinetics and Biopharmaceutics, 1990
- 'Vasoconstriction'--skin blanching--assay for glucocorticoids--a critiqueArchives of Dermatology, 1989
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987
- Are generic formulations equivalent to trade name topical glucocorticoids?Archives of Dermatology, 1987
- FDA 75/75 Rule: A ResponseJournal of Pharmaceutical Sciences, 1983
- Tetracycline. Another example of generic bioinequivalenceJAMA, 1978
- Equivalence lack in digoxin plasma levels1973
- Bioavailability of DigoxinNew England Journal of Medicine, 1971
- Variation in Biologic Availability of Digoxin from Four PreparationsNew England Journal of Medicine, 1971
- Pseudoxanthoma ElasticumArchives of Dermatology, 1962